Savara to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceBusiness Wire • 09/05/23
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 07/13/23
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Business Wire • 06/26/23
Savara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/30/23
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business Wire • 02/28/23
Savara Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/10/22
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022Business Wire • 09/06/22
Savara to Present at H.C. Wainwright 24th Annual Global Investment ConferenceBusiness Wire • 09/01/22
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Business Wire • 08/25/22
Savara Reports Second Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 08/11/22
Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022Business Wire • 07/11/22
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled BiologicBusiness Wire • 06/16/22